TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A retrospective cohort analysis found lower estimated obesity-related cancer risk among GLP-1 receptor agonist users than among insulin or sulfonylurea users. The difference was most apparent in patients with lower-severity diabetes; researchers found no consistent difference versus metformin, DPP-4 inhibitors or SGLT2 inhibitors. The study does not show that GLP-1 drugs prevent cancer.
A retrospective analysis of 359,595 adults with type 2 diabetes found that GLP-1 receptor agonist use was associated with lower estimated risk of obesity-related cancers than insulin or sulfonylureas, with the clearest differences among people with lower-severity diabetes. The study found no significant difference versus metformin, DPP-4 inhibitors or SGLT2 inhibitors, and does not establish that any medication prevents or causes cancer.
Researchers used electronic health record data from PCORnet for adults treated at a single center between January 2010 and July 2025. They conducted separate active-comparator analyses, comparing GLP-1 receptor agonists with five categories of diabetes medication and examining results by diabetes severity. Severity was classified using complications recorded before treatment, including vascular disease, kidney disease and other cardiometabolic conditions.
At three years, the estimated risk of obesity-related cancer was 2.01% among GLP-1 users and 3.26% among insulin users. In a separate comparison, the estimates were 2.85% for GLP-1 users and 3.98% for sulfonylurea users. These are study estimates from observational comparisons, not proof that the drugs themselves caused the differences.
The hazard ratio for GLP-1 treatment versus insulin was 0.62 in the overall analysis and 0.61 among patients with lower-severity diabetes; both results were statistically significant. Against sulfonylureas, the corresponding three-year hazard ratios were 0.67 overall and 0.62 in the low-severity group. At five years, comparisons continued to favor GLP-1 drugs over insulin and sulfonylureas in most severity categories, though not every result reached statistical significance.
Cancer Findings Depend on the Comparator
The findings matter because people with diabetes may take different medications at different stages of illness, and comparisons between those groups can reflect more than the drugs’ effects. The study suggests that which medication GLP-1 drugs are compared with and a patient’s baseline diabetes severity both shape the cancer-risk associations observed.
For patients and clinicians, this is not evidence to select a diabetes drug for cancer prevention. The authors said treatment decisions should continue to reflect established metabolic, cardiovascular and kidney benefits, as well as individual needs. They cautioned against changing an otherwise appropriate treatment solely because of these cancer findings.
Products Worth Considering
Instant Pot Pro 6-Quart 10-in-1 Electric Pressure Cooker, Black
Instant Pot Rio Wide 7.5 Qt 7-in-1 Electric Pressure Cooker, WhisperQuiet
Instant Pot Pro 8-Quart 10-in-1 Electric Pressure Cooker, Black
As an affiliate, we earn on qualifying purchases.
How Researchers Compared Treatments
Obesity and diabetes are each associated with higher cancer risk, and earlier observational studies have reported associations between GLP-1 drugs and lower risk for some obesity-related cancers. Those findings do not by themselves establish that the medication caused a reduction. This analysis adds a comparison across multiple diabetes drug classes and separates results by pre-treatment disease severity.
The researchers described the work as a set of retrospective, active-comparator cohort analyses. Outcomes were assessed at three and five years after treatment began. The design was intended to identify circumstances in which associations appeared, rather than prove that one treatment was superior for cancer outcomes. Propensity matching and other adjustments can address some differences between groups, but they cannot remove all possible confounding in non-randomized data.
“When we talk about GLP-1 receptor agonists and cancer risk, we need to ask, ‘compared with which medication, and in which patients?'”
— Jesús Gibran Hernández-Pérez, PhD, of UT Southwestern Medical Center, speaking to MedPage Today
Limits of the Cancer Comparisons
The analysis cannot determine whether the observed risk differences were caused by the medications. Patients prescribed insulin, sulfonylureas or GLP-1 drugs may differ in illness duration, prior treatment, health status and other factors that are difficult to fully account for. The researchers noted that treatment choices often reflect disease stage and clinical reasons, which can influence comparisons even after statistical adjustment.
Results also varied by severity and follow-up period. For patients with the most severe diabetes, the three-year GLP-1 versus sulfonylurea estimate trended toward higher cancer risk with GLP-1 treatment, but the difference was not statistically significant. Patients with moderate or severe diabetes had better outcomes with SGLT2 inhibitors during the first three years in the reported comparison. The supplied findings do not establish what explains these patterns, and they do not provide a basis for predicting an individual patient’s cancer risk.
Clinical Decisions Remain Individual
The report describes outcomes through five years, but the supplied material does not identify a scheduled follow-up study or a planned change to clinical guidance. Further research, including studies designed to better address differences between patients receiving each treatment, would be needed to clarify whether the observed associations reflect medication effects or underlying patient characteristics.
For now, the study’s authors advise against changing treatment solely to lower cancer risk. Patients considering a change should discuss the benefits and risks of their diabetes medicines with a qualified health professional. The analysis adds evidence about how cancer-risk associations vary by comparator and disease severity, but does not establish a cancer-prevention benefit.
Key Questions
Did the study show that GLP-1 drugs prevent cancer?
No. It found associations in retrospective data and did not establish that GLP-1 drugs prevent cancer.
Which comparisons showed lower estimated cancer risk with GLP-1 drugs?
The analysis found lower estimated obesity-related cancer risk versus insulin and sulfonylureas, with the clearest statistically significant results in the overall group and among patients with lower-severity diabetes.
Did GLP-1 drugs have lower risk than every diabetes medication?
No significant difference was reported versus metformin, DPP-4 inhibitors or SGLT2 inhibitors. The findings also varied by diabetes severity and follow-up period.
Should a patient change diabetes medication because of this study?
The study’s lead researcher said he would not recommend changing an otherwise appropriate treatment solely to reduce cancer risk based on these results. Medication decisions should be discussed with a qualified health professional.
Source: medpagetoday.com
